Remove 2018 Remove Disease Remove Radiopharmaceuticals
article thumbnail

Pharmacist sentenced in radiopharmaceutical criminal case

AuntMinnie

Evidence showed that Sheriff owned and was pharmacist in charge at Shertech, a pharmacy that provided nuclear and radiopharmaceutical drugs to medical facilities. The resulting diluted product was used in procedures such as renal scans to diagnose various illnesses, such as kidney disease.

article thumbnail

Targeted radiopharmaceuticals offer new hope for longer 'healthspans'

AuntMinnie

However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. A 2018 study from the U.S. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. Mark Crockett, MD, chief medical officer at TeleDaaS.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

Will new CPT codes spark utilization of quantitative MRI?

AuntMinnie

The timing of the new codes dovetails with advances in neuroimaging, such as in the assessment of white-matter diseases. In 2018, Alosco received nearly $800,000 from the National Institutes of Health's National Institute of Neurological Disorders and Stroke for the research. The work builds on previous research.

MRI 105
article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We